PriceTargets.com logo

OncoCyte - OCX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.42
  • Forecasted Upside: 60.61%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.75 As of 11/20/2024 01:00 AM ET
▲ +0.2 (7.84%)

This chart shows the closing price for OCX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OncoCyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCX

Analyst Price Target is $4.42
▲ +60.61% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OncoCyte in the last 3 months. The average price target is $4.42, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 60.61% upside from the last price of $2.75.

This chart shows the closing price for OCX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in OncoCyte. This rating has held steady since July 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
10/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.25 ➝ $4.25
5/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.25
4/24/2024Needham & Company LLCBoost TargetBuy ➝ Buy$3.60 ➝ $4.25
4/17/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$4.00
4/15/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00
11/13/2023Piper SandlerLower TargetNeutral ➝ Neutral$3.50 ➝ $3.00
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$4.25 ➝ $3.60
8/24/2023BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$9.00 ➝ $5.00
8/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$9.00 ➝ $4.25
4/4/2023Needham & Company LLCLower TargetBuy$28.00 ➝ $9.00
12/1/2022Lake Street CapitalDowngradeBuy ➝ Hold$60.00 ➝ $10.00
11/17/2022BenchmarkLower Target$60.00
11/17/2022Piper SandlerDowngradeOverweight ➝ Neutral$20.00 ➝ $10.00
11/14/2022Piper SandlerLower TargetOverweight ➝ Overweight$30.00 ➝ $20.00
11/11/2022Needham & Company LLCLower TargetBuy$42.00 ➝ $28.00
8/17/2022Piper SandlerBoost TargetOverweight$28.00 ➝ $30.00
8/11/2022Lake Street CapitalLower TargetBuy$120.00 ➝ $60.00
8/11/2022Needham & Company LLCLower TargetBuy$45.00 ➝ $42.00
5/24/2022StephensDowngradeOverweight ➝ Equal Weight
5/15/2022Piper SandlerLower Target$36.00 ➝ $28.00
3/17/2022Piper SandlerLower TargetOverweight$62.00 ➝ $36.00
3/11/2022Lake Street CapitalLower TargetBuy$220.00 ➝ $120.00
3/11/2022Needham & Company LLCLower TargetBuy$100.00 ➝ $80.00
1/7/2022StephensInitiated CoverageOverweight$62.00
12/17/2021BTIG ResearchReiterated RatingBuy$100.00
12/16/2021Needham & Company LLCLower TargetBuy$140.00 ➝ $100.00
11/10/2021Needham & Company LLCLower TargetBuy$160.00 ➝ $140.00
10/13/2021Needham & Company LLCReiterated RatingBuy$160.00
6/16/2021Needham & Company LLCReiterated RatingBuy$160.00
3/17/2021Needham & Company LLCReiterated RatingBuy$160.00
3/17/2021BenchmarkBoost TargetBuy$120.00 ➝ $220.00
2/10/2021Piper SandlerBoost Target$80.00 ➝ $140.00
1/7/2021BenchmarkUpgradeSpeculative Buy ➝ Buy$120.00
12/16/2020Piper SandlerUpgradeOverweight$40.00 ➝ $80.00
11/30/2020BTIG ResearchInitiated CoverageBuy$100.00
11/13/2020Piper SandlerBoost TargetNeutral$30.00 ➝ $40.00
11/13/2020Needham & Company LLCBoost TargetBuy$40.00 ➝ $80.00
11/10/2020KeyCorpInitiated CoverageOverweight$100.00
11/9/2020KeyCorpInitiated CoverageOverweight$100.00
10/21/2020Needham & Company LLCReiterated RatingBuy$40.00
10/2/2020Needham & Company LLCReiterated RatingBuy$40.00
7/30/2020BenchmarkLower TargetSpeculative Buy$140.00 ➝ $120.00
6/30/2020Chardan CapitalDowngradeBuy ➝ Neutral
6/30/2020Needham & Company LLCInitiated CoverageBuy$80.00
6/30/2020Piper SandlerDowngradeOverweight ➝ Neutral
6/30/2020Lake Street CapitalLower TargetBuy$120.00 ➝ $80.00
6/25/2020Piper SandlerBoost TargetOverweight$108.00 ➝ $150.00
6/17/2020Needham & Company LLCReiterated RatingBuy$80.00
6/2/2020Needham & Company LLCInitiated CoverageBuy$80.00
5/13/2020Chardan CapitalReiterated RatingBuy$155.00
3/26/2020Chardan CapitalReiterated RatingBuy$155.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
OncoCyte logo
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More

Today's Range

Now: $2.75
Low: $2.50
High: $2.78

50 Day Range

MA: $2.99
Low: $2.55
High: $3.34

52 Week Range

Now: $2.75
Low: $2.29
High: $4.34

Volume

25,364 shs

Average Volume

64,563 shs

Market Capitalization

$46.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of OncoCyte?

The following Wall Street sell-side analysts have issued stock ratings on OncoCyte in the last year: Benchmark Co., Needham & Company LLC, Stephens, and StockNews.com.
View the latest analyst ratings for OCX.

What is the current price target for OncoCyte?

0 Wall Street analysts have set twelve-month price targets for OncoCyte in the last year. Their average twelve-month price target is $4.42, suggesting a possible upside of 60.6%. Benchmark Co. has the highest price target set, predicting OCX will reach $5.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $4.00 for OncoCyte in the next year.
View the latest price targets for OCX.

What is the current consensus analyst rating for OncoCyte?

OncoCyte currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OCX.

What other companies compete with OncoCyte?

Other companies that are similar to OncoCyte include Achilles Therapeutics, DBV Technologies, ImmuCell, DURECT and Aspira Women's Health. Learn More about companies similar to OncoCyte.

How do I contact OncoCyte's investor relations team?

OncoCyte's physical mailing address is 15 CUSHING, IRVINE CA, 92618. The company's listed phone number is (949) 409-7600 and its investor relations email address is [email protected]. The official website for OncoCyte is oncocyte.com. Learn More about contacing OncoCyte investor relations.